How to manage lower-risk myelodysplastic syndromes

Leukemia

Volumn 26, Issue 3, 2012, Pages 390-394

  Sekeres, M A ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

MDS; outcomes; therapy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; LENALIDOMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; THYMOCYTE ANTIBODY;

BLOOD TRANSFUSION; CLINICAL DECISION MAKING; DRUG EFFICACY; ERYTHROPOIESIS; HUMAN; MYELOBLAST; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; SCORING SYSTEM;

ANEMIA; HUMANS; IRON CHELATING AGENTS; MYELODYSPLASTIC SYNDROMES;

EID: 84857992233     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.223     Document Type: Review

References (57)

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199. (Pubitemid 12073508)
2. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 Revisions of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951.
3. Allampallam K, Shetty V, Mundle S, Dutt D, Kravitz H, Reddy PL et al. Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. Int J Hematol 2002; 75: 289-297. (Pubitemid 43014062)
4. Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001; 97: 1427-1434. (Pubitemid 32183769)
5. Kitagawa M, Saito I, Kuwata T, Yoshida S, Yamaguchi S, Takahashi M et al. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 1997; 11: 2049-2054. (Pubitemid 28043688)
6. Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, O'Keefe C et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009; 113: 1315-1325.
7. Tiu RV, Gondek LP, O'Keefe CL, Elson P, Huh J, Mohamedali A et al. Prognostic impact of SNP array karyotyping in myelodys-plastic syndromes and related myeloid malignancies. Blood 2011; 117: 4552-4560.
8. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007; 109: 1536-1542. (Pubitemid 46595689)
9. Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008; 112: 45-52.
10. Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 1992; 82: 358-367.
11. Maynadie M, Verret C, Moskovtchenko P, Mugneret F, Petrella T, Caillot D et al. Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. Br J Cancer 1996; 74: 288-290. (Pubitemid 26254146)
12. McNally RJ, Rowland D, Roman E, Cartwright RA. Age and sex distributions of hematological malignancies in the UK. Hematol Oncol 1997; 15: 173-189. (Pubitemid 28374886)
13. Radlund A, Thiede T, Hansen S, Carlsson M, Engquist L. Incidence of myelodysplastic syndromes in a Swedish population. Eur J Haematol 1995; 54: 153-156.
14. Sekeres MA, Schoonen WM, Kantarjian H, List A, Fryzek J, Paquette R et al. Characteristics of USA patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst 2008; 100: 1542-1551.
15. Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008; 113: 1351-1361.
16. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23: 7594-7603. (Pubitemid 46291823)
17. Sekeres MA, Maciejewski JP, List AF, Steensma DP, Artz A, Swern AS et al. Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based survey. Oncologist 2011; 16: 904-911.
18. Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Perez WS, Anasetti C et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004; 104: 579-585. (Pubitemid 38900045)
19. Casadevall N, Durieux P, Dubois S, Hemery F, Lepage E, Quarre MC et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 2004; 104: 321-327. (Pubitemid 38900010)
20. Terpos E, Mougiou A, Kouraklis A, Chatzivassili A, Michalis E, Giannakoulas N et al. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. Br J Haematol 2002; 118: 174-180. (Pubitemid 34779534)
21. Musto P, Falcone A, Sanpaolo G, Bodenizza C, La Sala A, Perla G et al. Efficacy of a single, weekly dose of recombinant erythro-poietin in myelodysplastic syndromes. Br J Haematol 2003; 122: 269-271. (Pubitemid 36859613)
22. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Italian cooperative study group for rHuEpo in myelodysplastic syndromes. Br J Haematol 1998; 103: 1070-1074.
23. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin+- granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003; 120: 1037-1046. (Pubitemid 36411563)
24. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl IM et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 1998; 92: 68-75. (Pubitemid 28303177)
25. Negrin RS, Stein R, Doherty K, Cornwell J, Vardiman J, Krantz S et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 1996; 87: 4076-4081. (Pubitemid 26152251)
26. Casadevall N, Durieux P, Dubois S, Hemery F, Lepage E, Quarre MC et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 2004; 104: 321-327. (Pubitemid 38900010)
27. Mantovani L, Lentini G, Hentschel B, Wickramanayake PD, Loeffler M, Diehl V et al. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. Br J Haematol 2000; 109: 367-375. (Pubitemid 30350720)
28. Jadersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellstrom-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 2005; 106: 803-811. (Pubitemid 41076418)
29. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995; 89: 67-71.
30. Jadersten M, Malcovati L, Dybedal I, Della Porta MG, Invernizzi R, Montgomery SM et al. Erythropoietin and granulocytecolony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008; 26: 3607-3613.
31. Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008; 111: 574-582.
32. Golshayan AR, Jin T, Maciejewski J, Fu AZ, Bershadsky B, Kattan MW et al. Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. Br J Haematol 2007; 137: 125-132. (Pubitemid 46474717)
33. Hellstrom-Lindberg E, Negrin R, Stein R, Krantz S, Lindberg G, Vardiman J et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 1997; 99: 344-351. (Pubitemid 27497565)
34. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin+- granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003; 120: 1037-1046. (Pubitemid 36411563)
35. Sekeres MA, Fu AZ, Maciejewski JP, Golshayan AR, Kalaycio ME, Kattan MW. A decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes. Cancer 2007; 109: 1125-1132. (Pubitemid 46435391)
36. Golshayan AR, Jin T, Maciejewski J, Fu AZ, Bershadsky B, Kattan MW et al. Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. Br J Haematol 2007; 137: 125-132. (Pubitemid 46474717)
37. Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci USA 2009; 106: 12974-12979.
38. Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008; 451: 335-339.
39. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456-1465. (Pubitemid 44511560)
40. Sekeres MA, Maciejewski JP, Giagounidis AA, Wride K, Knight R, Raza A et al. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2008; 26: 5943-5949.
41. Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008; 111: 86-93.
42. Germing U, Lauseker M, Hildebrandt B, Symeonidis A, Cermak J, Pfeilstocker M et al. Survival, prognostic factors, and rates of leukemic transformation in a multicenter study of 303 untreated patients with MDS and del(5q). ASH Annual Meeting Abstracts 2009; 114: 945.
43. Sekeres MA, Giagounidis A, List AF, Sanz G, Selleslag D, Backstrom J et al. Predictive factors for overall survival (OS) and AML progression in a large cohort of patients with low-/Int-1-risk mds with del(5Q) treated with lenalidomide (LEN). European Haematology Association Annual Meeting 2011, 481.
44. Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 2009; 28: 437-444.
45. Sekeres MA, Kantarjian H, Fenaux P, Becker P, Boruchov A, Guerci-Bresler A et al. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer 2011; 117: 992-1000.
46. Passweg JR, Giagounidis AA, Simcock M, Aul C, Dobbelstein C, Stadler M et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care-SAKK 33/99. J Clin Oncol 2011; 29: 303-309.
47. Saunthararajah Y, Nakamura R, Wesley R, Wang QJ, Barrett AJ. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 2003; 102: 3025-3027. (Pubitemid 37248879)
48. Sekeres MA, Maciejewski JP, Donley DW, Grinblatt DL, Narang M, Malone III JM et al. A study comparing dosing regimens and efficacy of subcutaneous to intravenous azacitidine (AZA) for the treatment of myelodysplastic syndromes (MDS). ASH Annual Meeting Abstracts 2009; 114: 3797.
49. Steensma DP. The relevance of iron overload and the appropriateness of iron chelation therapy for patients with myelodysplastic syndromes: a dialogue and debate. Curr Hematol Malig Rep 2011; 6: 136-144.
50. Steensma DP. The role of iron chelation therapy for patients with myelodysplastic syndromes. J Natl Compr Canc Netw 2011; 9: 65-75.
51. Steensma DP. Myelodysplasia paranoia: iron as the new radon. Leuk Res 2009; 33: 1158-1163.
52. Tefferi A, Stone RM. Iron chelation therapy in myelodysplastic syndromeFcui bono? Leukemia 2009; 23: 1373.
53. Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006; 91: 873-880. (Pubitemid 44023139)
54. Raza A, Galili N, Smith S, Godwin J, Lancet J, Melchert M et al. Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TelintraTM, TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome. Blood 2009; 113: 6533-6540.
55. Garcia-Manero G, Gore SD, Cogle CR, Jabbour EJ, Ward MR, MacBeth KJ et al. Evaluation of oral azacitidine using extended treatment schedules: a phase I study. ASH Annual Meeting Abstracts 2010; 116: 603.
56. Sloand EM, Olnes MJ, Shenoy A, Weinstein B, Boss C, Loeliger K et al. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. J Clin Oncol 2010; 28: 5166-5173.
57. Kurzrock R, Angevin E, Cohen S, Van Laethem J, Rijnbeek B, Vermeulen J et al. Siltuximab treatment increases hemoglobin (Hb) levels: preliminary results from a prospective phase 1 study in refractory solid tumors. ASH Annual Meeting Abstracts 2010; 116: 5150.